Form 4: Forminard Elizabeth sold JNJ
Forminard Elizabeth (EVP, Chief Legal Officer at JOHNSON & JOHNSON) reported an open-market sale of 13,072 shares of JNJ at an average $284.39, roughly $3,717,546, in a Form 4 filed 2026-11-13.
Past performance does not predict future results. Informational only, not investment advice.
Forminard Elizabeth (EVP, Chief Legal Officer at JOHNSON & JOHNSON) reported an open-market sale of 13,072 shares of JNJ at an average $284.39, roughly $3,717,546, in a Form 4 filed 2026-11-13.
JNJ presents an attractive long-term value and dividend play for portfolio diversification. The author views it as a stable holding with solid fundamentals despite moderating near-term growth expectations.
Schmid Timothy (EVP, WW Chair, MedTech at JOHNSON & JOHNSON) reported an open-market sale of 33,597 shares of JNJ at an average $274.74, roughly $9,230,440, in a Form 4 filed 2026-09-04.
Taubert Jennifer L (EVP, WWC. Innovative Medicine at JOHNSON & JOHNSON) reported an open-market sale of 15,000 shares of JNJ at an average $263.36, roughly $3,950,400, in a Form 4 filed 2026-08-18.
End of results.